Non-Overweight Patients with Nonalcoholic Fatty Liver Disease, Diabetes Fare Worse Than Overweight Patients Before and After Liver Transplant

ALEXANDRIA, Va. – A new study has found that people with nonalcoholic fatty liver disease (NAFLD) cirrhosis who are not overweight and are on a waiting list for a liver transplant fare worse than overweight patients before and after transplant surgery. The study concludes that these at-risk patients need better nutritional counseling and other interventions to help prevent serious health problems while they are waiting for liver transplant.

Researchers at the Yale School of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School will present the study this week at The Liver Meeting Digital Experience™ held by the American Association for the Study of Liver Diseases.

Although both obesity and diabetes are known independent risk factors for NAFLD cirrhosis, too little is known about how underweight and normal-weight patients with NAFLD fare before and after liver transplant. Information about the role of diabetes in poor patient outcomes, including early removal from liver transplant waiting lists and even post-transplant death, is also limited.

“NAFLD is one of the leading etiologies of liver disease among adults awaiting liver transplantation, and non-overweight individuals with NAFLD represent a subset of patients with a distinct risk factor profile characterized by increased visceral adipose tissue, underlying insulin resistance and genetic predisposition,” said Pedro Ochoa-Allemant, MD, the study’s lead researcher and resident physician at the department of internal medicine at the Yale School of Medicine. “Despite an apparent healthy status with lower body mass index, these patients have increased cardiometabolic risk factors, such as diabetes, that are associated with subsequent worse outcomes throughout the transplant process.”

The study found that non-overweight patients on a liver transplant waiting list were more likely than overweight or obese patients to:

- Be female, be older, have public insurance and have a low liver function.
- Have ascites, or fluid buildup in the abdomen, from severe liver disease and hepatic encephalopathy.
- Have a transjugular intrahepatic portosystemic shunt — a passage surgically created to allow fluid to move from one organ to another.
- Be removed early from liver transplant waitlists.
- Die after a liver transplant.
Compared with overweight patients who did not have diabetes, non-overweight patients with diabetes on a transplant list:

- Had even higher rates of severe outcomes.
- Had significantly higher rates of waitlist removal.
- Needed better nutritional counseling and healthy lifestyle interventions to help them lower their risk of severe outcomes as they waited for a new liver and after they had transplant surgery.

Non-overweight patients died after liver transplants at a higher rate than overweight patients whether they had diabetes or not.

“Our study suggests that non-overweight individuals with NAFLD cirrhosis have higher rates of waitlist removal due to clinical deterioration, as well as worse post-transplant survival compared with their overweight and obese counterparts,” said Ochoa-Allemant. “Therefore, it is crucial to identify these individuals at higher risk for adverse outcomes and effectively intervene by enhancing nutritional support, promoting physical activity and investigating other potential metabolic interventions to minimize risk before and after liver transplantation.”

The researchers identified 24,127 people with NAFLD who were on liver transplant waiting lists from Feb.2002, through June 2020, from the United Network for Organ Sharing database. Of these individuals, 6.8 percent were non-overweight, with a body mass index (BMI) between 18.5 and 24.9 kg/m2, and 93.2 percent were overweight or obese, with a BMI above this range.

Dr. Ochoa-Allemant’s poster entitled “Non-Overweight NAFLD and Diabetes Impact Outcomes in NAFLD Cirrhosis on Transplant Waitlist: A UNOS Analysis” (1505) has been designated a poster of distinction and can be viewed at The Liver Meeting Digital Experience™. The corresponding abstract can be found in the journal HEPATOLOGY.

About AASLD
AASLD is the leading organization of clinicians and researchers committed to preventing and curing liver disease. The work of our members has laid the foundation for the development of drugs used to treat patients with viral hepatitis. Access to care and support of liver disease research are at the center of AASLD’s advocacy efforts.

News releases and additional information about AASLD are available online at www.aasld.org.